USFDA completes surveillance inspection at Granules India’s Jeedimetla facility

23 Jun 2023 Evaluate

US Food & Drug Administration (USFDA) has successfully completed surveillance inspection at Granules India’s Jeedimetla facility located at Hyderabad, Telangana, India from June 19, 2023 to June 23, 2023 with zero (0) 483 observations. Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

393.40 -17.60 (-4.28%)
09-May-2024 15:53 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1493.35
Dr. Reddys Lab 5879.05
Cipla 1358.80
Zydus Lifesciences 967.80
Lupin 1585.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.